Inovio Sees Fda Decision This Thirty day period on Vaccine Demo Resumption

Inovio Pharmaceuticals  (INO) – Get Report said Monday it expects to hear from the Food stuff and Drug Administration this thirty day period on no matter whether its COVID-19 vaccine candidate can resume late-stage trials. 

Late trials of Inovio’s  coronavirus vaccine candidate — INO-4800 — have been below a “partial clinical hold” from the Food and Drug Administration since late September. 

The company said in its most recent quarterly earnings launch Monday that it “anticipates a reaction from the Food and drug administration this month as to whether or not the planned Section 2/3 scientific demo of INO-4800 can commence.”